Angion Biomedica Corp Stock News
$7.60
5.24%
day before yesterday
Nasdaq,
Jun 13, 10:00 pm CET
Angion Biomedica Corp Stock News
Neutral
GlobeNewsWire
●
11 days ago
Funding expected to support operations into Q1 2026. Anticipated AMPLIFY-7P Phase 2 interim analysis expected in Q3 2025.
Neutral
GlobeNewsWire
●
about one month ago
Interim analysis focused on disease-free survival (“DFS”) in randomized Phase 2 AMPLIFY-7P clinical trial expected in Q3 2025
Neutral
GlobeNewsWire
●
about 2 months ago
BOSTON, April 16, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on April 15, 2025, Elicio granted inducement awards to Elicio's newly appointed Chief Strategy and Financial Officer, Preetam Shah, and two a...
Neutral
GlobeNewsWire
●
3 months ago
Completed enrollment of Phase 2 AMPLIFY-7P randomized study; disease-free survival (“DFS”) event-driven interim analysis expected in Q3 2025
Neutral
GlobeNewsWire
●
3 months ago
BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer, effective as of the date hereof.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
